Cytisinicline

Name: Cytisinicline in Smoking cessation: Dosage forms and strengths
Published: 2026-09-14T15:39:06-04:00

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

3 evidence topics · 3 sources

U.S. investigational phase 3 formulation

“tablets containing 3 mg of cytisinicline” (opens the source at this quote in a new tab)

United Kingdom marketed formulation

Field	Quoted record
Dosage form	“Tablet”
Strength per tablet	“1.5 mg”

MedChemExpress research reagent, HY-N0175

“Product name : Cytisinicline” (opens the source at this quote in a new tab)
“Catalog No. : HY-N0175” (opens the source at this quote in a new tab)
“Caution: Product has not been fully validated for medical applications. For research use only.” (opens the source at this quote in a new tab)